Literature DB >> 17628700

Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients.

Paola Sarchielli1, Massimiliano Di Filippo, Antonio Candeliere, Davide Chiasserini, Alessia Mattioni, Serena Tenaglia, Michele Bonucci, Paolo Calabresi.   

Abstract

The present study was aimed at confirming the presence of GluR3 on T lymphocytes and to assess the effect of glutamate on proliferative responses to myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) and chemotactic migration to CXCL12/stromal cell-derived factor-1, RANTES, and MIP-1alpha in 15 control subjects and 20 relapsing-remitting multiple sclerosis (MS) patients (10 in a stable clinical phase and 10 during relapse). T lymphocytes of control subjects and MS patients express both mRNA and protein of GluR3 receptors, as shown by RT-PCR and immunoblot analyses. An up-regulation was evident during relapse and in patients with neuroradiological evidence of disease activity. Glutamate and AMPA at concentrations of 10 nM to 10 muM were able to enhance T lymphocyte proliferation to MBP and MOG and the chemotactic migration of T cells both in controls and MS patients. In the latter group, significantly higher proliferation values in response to glutamate were found in patients assessed during relapse and in those with gadolinium (Gd)+ enhancing lesions on MRI. Glutamate concentrations above 10 muM appeared to be inhibitory on MBP and MOG-specific T-lymphocyte proliferation as well as chemotactic response in both patients and controls. Higher GluR3 expression and higher activating effect of glutamate on T cells of MS patients during relapses and with evidence of disease activity on MRI suggests the involvement of glutamate-mediated mechanisms in the T-cell detrimental effects. In MS patients, glutamate within physiological ranges in the cerebrospinal fluid and brain extracellular space might enhance myelin antigen-specific proliferation and chemotactic migration via activation of AMPA receptors, which can be relevant for myelin and neuronal damage in MS. Excess glutamate levels seem to induce an inhibitory effect on lymphocyte function, and therefore the detrimental effect of this excitatory amino acid in this case could be attributed to a direct toxicity on glial and neuronal cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628700     DOI: 10.1016/j.jneuroim.2007.05.021

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Emerging roles for platelets as immune and inflammatory cells.

Authors:  Craig N Morrell; Angela A Aggrey; Lesley M Chapman; Kristina L Modjeski
Journal:  Blood       Date:  2014-02-28       Impact factor: 22.113

3.  Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.

Authors:  Hwa Jin Lee; Brian A Wall; Janet Wangari-Talbot; Seung-Shick Shin; Stephen Rosenberg; Joseph L-K Chan; Jin Namkoong; James S Goydos; Suzie Chen
Journal:  Clin Cancer Res       Date:  2011-08-15       Impact factor: 12.531

Review 4.  Glutamate, T cells and multiple sclerosis.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2017-02-24       Impact factor: 3.575

Review 5.  The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells.

Authors:  Yonatan Ganor; Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-03-02       Impact factor: 3.575

6.  Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection.

Authors:  Ivorlyne P Greene; Eun-Young Lee; Natalie Prow; Brownhilda Ngwang; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

Review 7.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

8.  Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease.

Authors:  Silvia Di Prisco; Elisa Merega; Tommaso Bonfiglio; Guendalina Olivero; Chiara Cervetto; Massimo Grilli; Cesare Usai; Mario Marchi; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

9.  Absence of system xc- on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis.

Authors:  Ellen Merckx; Giulia Albertini; Magdalena Paterka; Cathy Jensen; Philipp Albrecht; Michael Dietrich; Joeri Van Liefferinge; Eduard Bentea; Lise Verbruggen; Thomas Demuyser; Lauren Deneyer; Jan Lewerenz; Geert van Loo; Jacques De Keyser; Hideyo Sato; Pamela Maher; Axel Methner; Ann Massie
Journal:  J Neuroinflammation       Date:  2017-01-13       Impact factor: 8.322

10.  Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains.

Authors:  Sven Saussez; Barbara Laumbacher; Gilbert Chantrain; Alexandra Rodriguez; Songhai Gu; Rudolf Wank; Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-07-17       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.